The Changing Landscape of Glomerular Disease Research and Treatment

Rapid advances in glomerular disease, from single-cell tech to biomarkers and phase 3 trials, are reshaping diagnosis and treatment.

APOL1 kidney disease highlights the need for community trust, increased screening, and stronger clinical trial participation.

Anti-nephrin autoantibodies are redefining minimal change disease and enabling more precise, steroid-sparing treatment strategies.

PLA2R antibodies are advancing precision care in membranous nephropathy and informing new surrogate endpoints through PARASOL.

The PARASOL initiative is reshaping glomerular disease trials through shared data and improved surrogate endpoints.

Experts outline a 2026 vision for glomerular disease care, including new endpoints, combination therapies, and gene therapy advances.